| ID | 56079 |
| JaLCDOI | |
| FullText URL | |
| Author |
Miyata, Yasuhiko
Department of Hematology, Nagoya Medical Center
Saito M. , Akiko
Clinical Research Center, Nagoya Medical Center
Yano, Takahiro
Department of Hematology, Tokyo Medical Center
Yoshida, Isao
Department of Hemato-oncology, Shikoku Cancer Center
Suehiro, Youko
Department of Hematology, Kyushu Cancer Center
Harada, Naoki
Department of Hematology, Kyushu Medical Center
Nagai, Hirokazu
Department of Hematology, Nagoya Medical Center
|
| Abstract | In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years.
|
| Keywords | rituximab
diffuse large B-cell lymphoma
open-label
single arm trial
|
| Amo Type | Clinical Study Protocol
|
| Publication Title |
Acta Medica Okayama
|
| Published Date | 2018-06
|
| Volume | volume72
|
| Issue | issue3
|
| Publisher | Okayama University Medical School
|
| Start Page | 315
|
| End Page | 318
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| Content Type |
Journal Article
|
| language |
English
|
| Copyright Holders | CopyrightⒸ 2018 by Okayama University Medical School
|
| File Version | publisher
|
| Refereed |
True
|
| PubMed ID |
